Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?

Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?

Source: 
Motley Fool
snippet: 

Earlier this year, Bristol-Myers Squibb (NYSE: BMY) made Nektar Therapeutics (NASDAQ: NKTR) a stock market darling by offering billions for rights to an experimental new cancer drug. Recently, a well-regarded analyst said the partnered treatment isn't worth a nickel and investors are getting worried Bristol may have made a terrible mistake.